HomeVBIVQ • OTCMKTS
add
VBI Vaccines Inc
Previous close
$0.00050
Day range
$0.00050 - $0.00050
Year range
$0.00020 - $0.051
Market cap
14.34K USD
Avg Volume
56.31K
P/E ratio
-
Dividend yield
-
Primary exchange
OTCMKTS
Market news
Financials
Income Statement
Revenue
Net income
| (USD) | Mar 2024info | Y/Y change |
|---|---|---|
Revenue | 1.21M | 150.31% |
Operating expense | 10.24M | -37.68% |
Net income | -17.90M | 35.50% |
Net profit margin | -1.47K | 74.23% |
Earnings per share | — | — |
EBITDA | -11.26M | 40.75% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Mar 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 12.60M | -68.82% |
Total assets | 75.44M | -41.27% |
Total liabilities | 80.91M | -3.03% |
Total equity | -5.47M | — |
Shares outstanding | 28.68M | — |
Price to book | -0.00 | — |
Return on assets | -36.18% | — |
Return on capital | -55.53% | — |
Cash Flow
Net change in cash
| (USD) | Mar 2024info | Y/Y change |
|---|---|---|
Net income | -17.90M | 35.50% |
Cash from operations | -11.77M | 45.65% |
Cash from investing | -151.00K | 71.72% |
Cash from financing | 843.00K | — |
Net change in cash | -11.09M | 50.13% |
Free cash flow | -4.40M | 70.09% |
About
Variation Biotechnologies Inc., also known as VBI Vaccines Inc., is a biopharmaceutical company, headquartered in Cambridge, Massachusetts, with research facilities in Ottawa, Ontario, Canada, and a research and manufacturing site in Rehovot, Israel. Its Ottawa facility has approximately thirty researchers working with National Research Council of Canada to produce a COVID-19 vaccine—VBI-2902. In August VBI received CA$56 million from the Government of Canada to prepare its vaccine for clinical trials by the end of 2020. The company's CEO, Jeff Baxter, said that VBI-2902 is cheaper to produce than other vaccines. Wikipedia
Founded
1965
Website
Employees
135
